AKT1 and B-cell chronic lymphocytic leukemia: Doxorubicin mediates resistance in chronic lymphocytic leukemia (CLL) by upregulating RhoA/RhoA kinase, Ras/ERK1-2, Akt, HIF-1α, and P-gp activities; simvastatin inhibits this effect, overcoming doxorubicin resistance [105].